Tracon Pharmaceuticals racks up $27 mln Series B

Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo Securities were placement agents for the financing. In addition to the funding, Paul Walker of NEA has been added to Tracon's board of directors while Bruce Steel of BioMed Ventures will become a board observer. Based in San Diego, Tracon develops treatments for cancer and age-related macular degeneration.

North AmericaUSBriefs